Jyong Biotech Ltd. Ordinary Shares
NASDAQ:MENSBiotechnology
Healthcare
$1.86 -1.41%
-$0.02 today
- Market cap
- $141.41M
- Beta
- 2.08
- P/E (TTM)
- -25.1
- EPS (TTM)
- -$0.06
52W Low $1.43High $67.00
Volume 0.07M
Average 0.10M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$2.61M
FY 2025 · Annual
Net Income
-$4.67M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 121K | 122K | 127K | 120K | 100K |
| Gross Profit | (121K) | (122K) | (127K) | (120K) | (100K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 1.56M | 1.29M | 1.07M | 927K | 731K |
| Selling, General & Admin | 845K | 1.54M | 1.73M | 1.13M | 1.78M |
| Operating Expenses | 2.4M | 2.83M | 2.8M | 2.06M | 2.51M |
| Depreciation & Amortization | 122K | 123K | 127K | 120K | 100K |
| EBITDA | (3.24M) | (5.74M) | (3.52M) | (1.86M) | (2.51M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (2.4M) | (2.83M) | (2.8M) | (2.06M) | (2.61M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 6K | 5K | 56K | 7K | 610K |
| Interest Expense | 835K | 765K | 757K | 1.04M | 2.54M |
| Other Income / Expenses | (1.79M) | (3.8M) | (1.6M) | (963K) | (2.06M) |
| Income Before Tax | (4.2M) | (6.63M) | (4.4M) | (3.02M) | (4.67M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (4.2M) | (6.63M) | (4.4M) | (3.02M) | (4.67M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.06) | (0.09) | (0.06) | (0.04) | (0.06) |
| EPS (Diluted) | (0.06) | (0.09) | (0.06) | (0.04) | (0.06) |
| 76.03M | 76.03M | 76.03M | 76.03M | 73.01M | |
| 76.03M | 76.03M | 76.03M | 76.03M | 73.01M |
MENS Earnings Waterfall · TTM
NASDAQ:MENS · Revenue to Net Income
Key Ratios
EPS$-0.09
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-142.7
P/S Ratio0.0
Analysis
$0 of revenue converted into -$4.7M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-0.09, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 20-F | 20-F filing | May 15, 2026 | |
| NT 20-F | NT 20-F filing | Apr 29, 2026 | |
| SC 13D | SC 13D filing | Apr 24, 2026 | |
| 3 | Initial statement of beneficial ownership | Apr 14, 2026 | |
| 3 | Initial statement of beneficial ownership | Apr 8, 2026 |
How much revenue does MENS generate?
Jyong Biotech Ltd. Ordinary Shares (MENS) reported $0.00 of revenue in fiscal 2025.
Is MENS profitable?
Jyong Biotech Ltd. Ordinary Shares (MENS) reported -$4.67M of net income.
Continue the stock analysis
Jump to another research area for this company.